ABEO
ABEONA THERAPEUTICS INC.
$5.53
0.00%
$315.2M
No data for this timeframe.
Vol
Market Cap$315.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders50 funds
Inst. Value$61.7M
Inst. Activity6 buys / 3 sells
Insider Activity0B / 18S
Insider Net $-$1.3M
Reddit Sentiment67° Warm
SEC Reports9
Press Releases3
Recent Activity
Jun 12, 2026
SEC
Board member Michael Amoroso resigned from Abeona Therapeutics' Board of Directors and its Nominating and Corporate Gove
8-K — Impact 2/10
Jun 10, 2026
SEC
Abeona Therapeutics filed an 8-K furnishing an updated investor presentation (Exhibit 99.1) under Item 7.01 for use in m
8-K — Impact 2/10
Jun 10, 2026
SEC
A cluster of insider sales at ABEO Therapeutics: CEO, CFO, Chief Commercial Officer, and Chief Legal Officer collectivel
CLUSTER — Impact 5/10
Jun 9, 2026
Insider
Seshadri Vishwas sold 31,916 shares
Chief Executive Officer @ $5.30 ($169.3K)
Jun 9, 2026
Insider
O'Malley Brendan M. sold 6,305 shares
SVP, Chief Legal Officer @ $5.30 ($33.4K)
Jun 9, 2026
Insider
Vazzano Joseph Walter sold 13,421 shares
Chief Financial Officer @ $5.30 ($71.2K)
Inst.
MORGAN STANLEY — TRIM
337,562 shares ($1.5M)
Inst.
GROUP ONE TRADING LLC — TRIM
209,607 shares ($939.0K)
Price Targets
$19.71
+256.5% upside
Strong Buy
Current $5.53
Low $14.00
Median $20.00
High $28.00
7 analysts
$14.00
$28.00
Analyst Ratings
5Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 19, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 10, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.23 ▲ +19.5% | $-0.29 — $-0.19 | 50% YoY | 3 |
| Next Q | $-0.11 ▲ +31.3% | $-0.20 — $-0.01 | -2% YoY | 3 |
| Current FY | $-0.68 ▲ +24.6% | $-0.95 — $-0.45 | 45% YoY | 3 |
| Next FY | $0.29 ▲ +19.4% | $-0.17 — $0.93 | 142% YoY | 3 |
Latest Reports
NEUTRAL
8-K
2/10
Board member Michael Amoroso resigned from Abeona Therapeutics' Board of Directors and its Nominating and Corporate Gove
Jun 12, 2026
NEUTRAL
8-K
2/10
Abeona Therapeutics filed an 8-K furnishing an updated investor presentation (Exhibit 99.1) under Item 7.01 for use in m
Jun 10, 2026
NEUTRAL
Press
3/10
Abeona Therapeutics announced the activation of NewYork-Presbyterian/Columbia University Irving Medical Center as its fi
Apr 2, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $14.3M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $9.7M | — |
| GOLDMAN SACHS GROUP INC | $5.1M | — |
| STATE STREET CORP | $4.3M | ADD |
| BALYASNY ASSET MANAGEMENT L.P. | $2.6M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Seshadri Vishwas | SELL | $169.3K |
| Jun 9, 2026 | O'Malley Brendan | SELL | $33.4K |
| Jun 9, 2026 | Vazzano Joseph | SELL | $71.2K |
| Jun 9, 2026 | Vasanthavada Madhav | SELL | $28.9K |
| Jun 8, 2026 | Seshadri Vishwas | SELL | $132.6K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
50 institutional holders with $61.7M total value (13,778,468 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, GOLDMAN. Net buying activity: 6 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3,195,530 | $14.3M | 23.2% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2,164,851 | $9.7M | 15.7% | — |
| 3 | GOLDMAN SACHS GROUP INC | 1,130,619 | $5.1M | 8.2% | — |
| 4 | STATE STREET CORP | 957,328 | $4.3M | 6.9% | ADD +25.5% |
| 5 | BALYASNY ASSET MANAGEMENT L.P. | 589,847 | $2.6M | 4.3% | DOUBLED +116.4% |
| 6 | CITIGROUP INC | 522,445 | $2.3M | 3.8% | ADD +25.8% |
| 7 | NATIONAL BANK OF CANADA /FI/ | 500,000 | $2.2M | 3.6% | — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 432,370 | $1.9M | 3.1% | — |
| 9 | BANK OF AMERICA CORP /DE/ | 394,274 | $1.8M | 2.9% | TRIM -44.4% |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 383,900 | $1.7M | 2.8% | — |
| 11 | VANGUARD FIDUCIARY TRUST CO | 339,515 | $1.5M | 2.5% | — |
| 12 | MORGAN STANLEY | 337,562 | $1.5M | 2.4% | TRIM -28.7% |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 292,400 | $1.3M | 2.1% | — |
| 14 | VANGUARD PORTFOLIO MANAGEMENT LLC | 270,976 | $1.2M | 2.0% | — |
| 15 | MARSHALL WACE, LLP | 216,305 | $969.0K | 1.6% | NEAR_EXIT -86.1% |
| 16 | GROUP ONE TRADING LLC | 209,607 | $939.0K | 1.5% | TRIM -35.3% |
| 17 | CITADEL ADVISORS LLC | 205,200 | $919.3K | 1.5% | — |
| 18 | PANAGORA ASSET MANAGEMENT INC | 199,145 | $892.2K | 1.4% | — |
| 19 | FMR LLC | 194,813 | $872.8K | 1.4% | DOUBLED +2812.4% |
| 20 | SEI INVESTMENTS CO | 172,460 | $772.6K | 1.3% | DOUBLED +142.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 473,661 | 337,562 | -28.7% | $1.5M | 2026-Q1 |
| GROUP ONE TRADING LLC | TRIM | 323,986 | 209,607 | -35.3% | $939.0K | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 71,153 | 172,460 | +142.4% | $772.6K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 116,200 | 161,082 | +38.6% | $721.6K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | NEAR_EXIT | 154,986 | 33,561 | -78.3% | $150.4K | 2026-Q1 |
| Brevan Howard Capital Management LP | ADD | 21,707 | 29,263 | +34.8% | $131.1K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 5 | 86 | +1620.0% | $385.00 | 2026-Q1 |
| CWM, LLC | ADD | 55 | 75 | +36.4% | $336.00 | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 24,127 | 31,005 | +28.5% | $139.00 | 2026-Q1 |
| CWM, LLC | TRIM | 94 | 55 | -41.5% | — | 2025-Q4 |
| STATE STREET CORP | ADD | 716,154 | 898,438 | +25.5% | $4.7M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 912,912 | 507,625 | -44.4% | $2.7M | 2025-Q4 |
| GROUP ONE TRADING LLC | DOUBLED | 48,000 | 323,986 | +575.0% | $1.7M | 2025-Q4 |
| FMR LLC | DOUBLED | 5,784 | 168,455 | +2812.4% | $887.8K | 2025-Q4 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 207,777 | 154,986 | -25.4% | $787.3K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 526,437 | 116,200 | -77.9% | $612.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 27,179 | 47,852 | +76.1% | $252.2K | 2025-Q4 |
| Russell Investments Group, Ltd. | ADD | 7,082 | 13,095 | +84.9% | $69.0K | 2025-Q4 |
| PNC FINANCIAL SERVICES GROUP, INC. | NEAR_EXIT | 482 | 5 | -99.0% | $26.00 | 2025-Q4 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | EXIT | 3,047,985 | 0 | -100.0% | $0.00 | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 329,884 | 912,912 | +176.7% | $4.8M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 969,276 | 607,641 | -37.3% | $3.2M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 299,937 | 526,437 | +75.5% | $2.8M | 2025-Q3 |
| Trexquant Investment LP | ADD | 127,195 | 177,754 | +39.7% | $938.5K | 2025-Q3 |
| MARSHALL WACE, LLP | NEAR_EXIT | 85,124 | 11,800 | -86.1% | $62.3K | 2025-Q3 |
10 unique insiders with 20 transactions. Net insider value: -$1.3M ($0.00 bought, $1.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Seshadri Vishwas | Chief Executive Officer | SELL | 31,916 | $5.30 | $169.3K |
| Jun 9, 2026 | O'Malley Brendan M. | SVP, Chief Legal Officer | SELL | 6,305 | $5.30 | $33.4K |
| Jun 9, 2026 | Vazzano Joseph Walter | Chief Financial Officer | SELL | 13,421 | $5.30 | $71.2K |
| Jun 9, 2026 | Vasanthavada Madhav | Chief Commercial Officer | SELL | 5,450 | $5.30 | $28.9K |
| Jun 8, 2026 | Seshadri Vishwas | Chief Executive Officer | SELL | 24,428 | $5.43 | $132.6K |
| Jun 8, 2026 | O'Malley Brendan M. | SVP, Chief Legal Officer | SELL | 4,826 | $5.43 | $26.2K |
| Jun 8, 2026 | Vazzano Joseph Walter | Chief Financial Officer | SELL | 10,271 | $5.43 | $55.8K |
| Jun 8, 2026 | Vasanthavada Madhav | Chief Commercial Officer | SELL | 4,170 | $5.43 | $22.6K |
| May 26, 2026 | Alvino Mark | Director | GIFT | 500 | — | — |
| May 22, 2026 | Alvino Mark | Director | SELL | 6,500 | $5.46 | $35.5K |
| May 15, 2026 | Crombez Eric | Director | SELL | 26,143 | $5.53 | $144.6K |
| May 11, 2026 | Vasanthavada Madhav | Chief Commercial Officer | SELL | 5,548 | $5.96 | $33.1K |
| Apr 1, 2026 | Goldan Keith A. | Director | AWARD | 32,751 | — | — |
| Mar 31, 2026 | Seshadri Vishwas | Chief Executive Officer | SELL | 29,985 | $4.38 | $131.5K |
| Mar 16, 2026 | Vazzano Joseph Walter | Chief Financial Officer | SELL | 785 | $4.76 | $3.7K |
| Feb 2, 2026 | Silverstein Christine Berni | Director | SELL | 20,070 | $5.09 | $102.2K |
| Feb 2, 2026 | Wuchterl Donald A. | Director | SELL | 14,814 | $5.09 | $75.4K |
| Feb 2, 2026 | Alland Leila | Director | SELL | 18,065 | $5.09 | $92.0K |
| Feb 2, 2026 | Crombez Eric | Director | SELL | 16,284 | $5.09 | $82.9K |
| Feb 2, 2026 | Alvino Mark | Director | SELL | 2,000 | $5.09 | $10.2K |
9 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 8 neutral. Avg impact: 3.3/10.
NEUTRAL
8-K
2/10
Board member Michael Amoroso resigned from Abeona Therapeutics' Board of Directors and its Nominatin
Jun 12, 2026
NEUTRAL
8-K
2/10
Abeona Therapeutics filed an 8-K furnishing an updated investor presentation (Exhibit 99.1) under It
Jun 10, 2026
BEARISH
CLUSTER
5/10
A cluster of insider sales at ABEO Therapeutics: CEO, CFO, Chief Commercial Officer, and Chief Legal
Jun 10, 2026
NEUTRAL
8-K
4/10
Abeona Therapeutics reported a constructive pre-IND meeting with the FDA regarding ABO-701, a novel
Jun 4, 2026
NEUTRAL
CLUSTER
2/10
Two directors at Abeona Therapeutics sold a total of $180K in open-market transactions within a week
May 22, 2026
NEUTRAL
PRESS-RELEASE
5/10
Abeona reported Q1 2026 net product revenue of $8.7M from ZEVASKYN, up from $2.4M in Q4 2025, with t
May 13, 2026
NEUTRAL
8-K
5/10
Abeona Therapeutics reported Q1 2026 net product revenue of $8.7M, up from $2.4M in Q4 2025, driven
May 13, 2026
NEUTRAL
DEFA14A
2/10
Abeona Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) on May 4, 2026,
May 4, 2026
NEUTRAL
8-K
3/10
Abeona Therapeutics appointed Keith A. Goldan to its Board of Directors and as Chair of the Audit Co
Apr 7, 2026
NEUTRAL
3/10
Abeona Therapeutics announced the activation of NewYork-Presbyterian/Columbia University Irving Medi
Apr 2, 2026
MIXED
6/10
Abeona Therapeutics reported its first full year of commercial operations following FDA approval of
Mar 17, 2026
NEUTRAL
3/10
Abeona Therapeutics announced it will discuss its fourth quarter and full year 2025 financial result
Mar 3, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 5 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$19.71 mean target
+256.5% upside
Strong Buy (3.00)
$14.00 Low
$28.00 High
| Metric | Value |
|---|---|
| Current Price | $5.53 |
| Target Low | $14.00 |
| Target Mean | $19.71 |
| Target Median | $20.00 |
| Target High | $28.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.23 | $-0.29 | $-0.19 | 50.0% | +19.5% | 0↑ 3↓ | $0.0B | 2940.0% | 3 |
| Next Q 2026-09-30 |
$-0.11 | $-0.20 | $-0.01 | -1.8% | +31.3% | 0↑ 3↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-0.68 | $-0.95 | $-0.45 | 44.7% | +24.6% | 0↑ 3↓ | $0.1B | 1025.6% | 3 |
| Next FY 2027-12-31 |
$0.29 | $-0.17 | $0.93 | 141.9% | +19.4% | 0↑ 3↓ | $0.1B | 106.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.233 | |
| 7d ago | $-0.290 | +0.057 |
| 30d ago | $-0.290 | +0.057 |
| 60d ago | $-0.193 | -0.040 |
| 90d ago | $-0.050 | -0.183 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 19, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 1, 2026
other
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">CLEVELAND, June 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards
May 26, 2026
other
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
<p align="justify">CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its managemen
May 15, 2026
short_volume
Short Volume: ABEO — 71.5% short (0.5M / 0.7M)
Short: 474,618 | Exempt: 1,401 | TRF Vol: 663,561 | Short Ratio: 71.5% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: ABEO — 62.0% short (0.4M / 0.7M)
Short: 434,361 | Exempt: 10 | TRF Vol: 700,111 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
<p align="center"><em>- Three patients treated with ZEVASKYN</em><sup><strong>®</strong></sup><em> in Q1 2026 -</em></p>
May 13, 2026
earnings_calendar
ABEO Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
short_volume
Short Volume: ABEO — 61.7% short (0.3M / 0.6M)
Short: 342,882 | Exempt: 100 | TRF Vol: 555,356 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: ABEO — 56.7% short (0.4M / 0.7M)
Short: 371,226 | Exempt: 1,000 | TRF Vol: 654,762 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
May 1, 2026
other
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards
Apr 22, 2026
short_volume
Short Volume: ABEO — 55.2% short (0.3M / 0.6M)
Short: 322,342 | Exempt: 2,000 | TRF Vol: 584,096 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
short_volume
Short Volume: ABEO — 78.9% short (0.6M / 0.7M)
Short: 585,722 | Exempt: 0 | TRF Vol: 742,220 | Short Ratio: 78.9% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
other
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
<p align="justify">CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A.
Apr 6, 2026
other
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity award
Apr 2, 2026
announcement
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
<p align="justify">CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presb
Mar 26, 2026
short_volume
Short Volume: ABEO — 68.9% short (0.4M / 0.6M)
Short: 408,194 | Exempt: 0 | TRF Vol: 592,462 | Short Ratio: 68.9% | Off-exchange volume (dark pool + OTC)